Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024 - Episode 7

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

, , ,

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

EP. 1: Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)
EP. 2: Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer
EP. 3: Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP. 4: Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP. 5: Emerging Data in Metastatic Urothelial Carcinoma
EP. 6: Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma
Now Viewing
EP. 7: Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma
EP. 8: Later-Line Therapies for Metastatic Urothelial Carcinoma
EP. 9: Treatment Sequencing Practices in Metastatic Urothelial Carcinoma
EP. 10: Exciting New Approaches in Metastatic Urothelial Carcinoma
EP. 11: Key Takeaways on Updates in Bladder Cancer

Related Content:

Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024Fox Chase Cancer CenterHuntsman Cancer Institute at the University of Utah University of North Carolina, Lineberger Comprehensive Cancer CenterFred Hutch Cancer CenterGenitourinary CancersOncLive Peer Exchange®
Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents
Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice